- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03758963
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
A Prospective, Multi-center, Randomized, Double-blinded (Subject & Independent Efficacy Evaluator), Comparative Clinical Study to Evaluate the Efficacy and Safety of SRT (Selective Retina Therapy) With 'R:GEN' in Patients With Central Serous Chorioretinopathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, treatment effect of each group will be evaluated by follow-up once a month of both study group and control group other than the 2nd month until 6 months following the first procedure.
For the primary efficacy evaluation, the percentage of subjects who show complete removal of sub-retinal fluid (SRF) in Optical Coherence Tomography (OCT) results will be evaluated in the study group, before SRF therapy and at 3 months after therapy, and in control group, before sham procedure using R:GEN and at 3 months after therapy. In addition, for secondary efficacy evaluation, major symptoms of central serous chorioretinopathy will be evaluated at 3 and 6 months including changes in best corrected visual acuity (BCVA) on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, the degree of retinal functional damage, and changes in sub-retinal fluid (SRF) and central macula thickness (CMT) on OCT. At 6 months, removal rate of leakage on Fluorescene Angiography (FA) and recurrence of the disease will be evaluated to compare the recurrence rate of study group and control group undergoing sham procedure.
The subjects in the study group who only meet the conditions of retreatment at 3 ~ 5 months after selective retina therapy (SRT) may receive SRT up to twice again.
The subjects in the control group those who have not recovered naturally but have persistent clinical symptoms at 3 months will undergo SRT. And the subjects in the control group who only meet the conditions of retreatment at 5 months after SRT at 2 months.
And the subjects in the control group, who have experienced complete disappearance of SRF at 3 months after Sham procedure, but SRF is observed again at 4 or 5 months, may receive SRT up to twice again.
These subjects will be categorized into a separate subgroup and the efficacy and safety of SRT will be evaluated every visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seongnam-si, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Korea University Anam Hospital
-
Seoul, Korea, Republic of
- The Catholic University of Korea Seoul St.Mary's Hospital
-
Seoul, Korea, Republic of
- Nune Eye Hospital
-
Seoul, Korea, Republic of
- The Catholic University of Korea Yeouido St.Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female adult patients aged 19 or over and less than 55
- Patients who have had clinical symptoms of central serous chorioretinopathy over 3 months.
- Patients whose best corrected visual acuity (BCVA) is at least 20/200 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (BCVA based on the ETDRS chart will be converted into logMAR)
- Patients with Sub-Retinal Fluid (SRF) that has been going into the fovea continuously
- Patients with ≥1 ~ ≤ 3 active leakage sites in Fundus Fluorescein Angiography (FA)
Patients who are of child-bearing potential and have agreed to use a medically acceptable contraceptive method during the study period
☞Medically acceptable contraceptive method: Condom, oral contraceptive pills that have been continued for more than three months, contraceptive injection or implants or intrauterine contraceptive device
- Patients who voluntarily agree to participate in this study, and are willing to and able to follow the protocol.
Exclusion Criteria:
- Patients with other retinal diseases such as choroidal neovascularization, polypoidal choroidal vasculopathy.
- Patients with the conditions that make laser therapy difficult such as cataract or vitreous cloudiness.
- Patients who have atrophy (diameter: ≥1000㎛) in the retinal pigment epithelium including the fovea.
- Patients who had undergone laser or photodynamic therapy for central serous chorioretinopathy prior to the study participation.
- Patients who have received steroid treatment (periocular, subtenon, intraocular) within the last one year
- Patients who have received intraocular injection of anti-Vascular Endothelial Growth Factor (anti-VEGF) agent within the last six months.
- Patients who have undergone ophthalmological surgery such as intraocular surgery or vitrectomy within the last six months.
- Patients who have taken medication for central serous chorioretinopathy such as acetazolamide, spironolactone, and kalidinogenase [within the last two months].
- Patients who have a history of allergy to fluorescein used for FA and indocyanine green used for ICG angiography.
- Female patients who are pregnant or breastfeeding.
- Patients with systemic diseases such as Cushing's syndrome, inflammatory diseases, uncontrolled hypertension and diabetes, liver diseases, kidney diseases.
- Patients who have pigment epithelial detachment that is directly related to the point of leakage with a diameter of more than 1000 μm.
- Patients who are considered ineligible for this study according to the investigator's judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Laser
|
Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues.
SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE.
Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered.
Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
|
Sham Comparator: Sham Laser procedure
|
Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues.
SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE.
Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered.
Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub-retinal Fluid (SRF) Removal Rate
Time Frame: 3 months
|
The percentage of subjects (%) who show complete removal of Sub-retinal Fluid (SRF) on Optical Coherence Tomography (OCT) is compared between study group and control group.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of Best Corrected Visual Acuity
Time Frame: 3, 6 months
|
The improvement of Best Corrected Visual Acuity is evaluated using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and is compared between study group and control group.
|
3, 6 months
|
Degree of Retinal Functional Damage
Time Frame: 3, 6 months
|
The degree of retinal functional damage is compared between study group and control group.
|
3, 6 months
|
Change in Sub-retinal Fluid (SRF)
Time Frame: 3, 6 months
|
The change in Sub-retinal Fluid (SRF) (μm, mm3) on Optical Coherence Tomography (OCT) is compared between study group and control group.
|
3, 6 months
|
Change in Central Macular Thickness
Time Frame: 3, 6 months
|
The change on Central Macular Thickness (CMT) (μm) based on Optical Coherence Tomography (OCT) results are compared between the study and control group.
|
3, 6 months
|
Removal Rate of Leakage
Time Frame: 6 months
|
The percentage (%) of participants who show complete removal of leakage in Fluorescene Angiography (FA) results is compared between study group and control group.
|
6 months
|
Recurrence Rate
Time Frame: 6 months
|
The percentage (%) of participants who show recurrence is compared between study group and control group
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Oh Woong Kwon, PhD, Nune Eye Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTN-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Serous Chorioretinopathy
-
Shiraz University of Medical SciencesRecruiting
-
Sun Yat-sen UniversityCompletedAcute Central Serous ChorioretinopathyChina
-
Ankara Universitesi TeknokentCompletedCentral Serous Chorioretinopathy | Chronic Central Serous ChorioretinopathyTurkey
-
Leiden University Medical CenterRadboud University Medical Center; Academisch Medisch Centrum - Universiteit...UnknownChronic Central Serous ChorioretinopathyNetherlands
-
Manhattan Eye, Ear & Throat HospitalAlcon Research; LuEsther T. Mertz Retinal Research CenterCompletedChronic Central Serous ChorioretinopathyUnited States
-
Radboud University Medical CenterOogziekenhuis RotterdamRecruitingChronic Central Serous ChorioretinopathyNetherlands
-
Radboud University Medical CenterUniversity of Oxford; University of Cologne; Leiden University Medical Center; University...CompletedChronic Central Serous ChorioretinopathyNetherlands, France, Germany, United Kingdom
-
Università degli Studi di BresciaUnknownChronic Central Serous Chorioretinopathy
-
Manhattan Eye, Ear & Throat HospitalLuEsther T. Mertz Retinal Research CenterCompletedChronic Central Serous ChorioretinopathyUnited States
-
Manhattan Eye, Ear & Throat HospitalCompletedChronic Central Serous ChorioretinopathyUnited States
Clinical Trials on R:GEN Selective Retina Therapy
-
University Hospital Schleswig-HolsteinSt Thomas; Medical Laser Center Lübeck, GermanyCompletedDiabetic Macular Edema
-
Insel Gruppe AG, University Hospital BernBern University of Applied SciencesRecruiting
-
University Hospital Inselspital, BerneTerminatedAge-related Macular Degeneration | Macular Edema | Retinal Vein Occlusion | Central Serous Chorioretinopathy | Retinal NeovascularizationSwitzerland
-
LUTRONIC CorporationUnknownDiabetic Macular EdemaKorea, Republic of
-
Kim's Eye HospitalCompleted
-
University of KielMedical Laser Center Lübeck, Lübeck, Germany; Institute for Medical Informaties...CompletedCentral Serous Chorioretinopathy | Selective Retina TherapyGermany
-
Rabin Medical CenterCompleted
-
Imperial College LondonBiocompatibles UK Ltd, a BT International group companyRecruitingNeuroendocrine Tumors | Liver MetastasesUnited Kingdom
-
Juan Carlos M. Andreani MDNot yet recruiting
-
Terumo Europe N.V.CompletedHepatocellular Carcinoma | Metastatic CancerNetherlands, Germany, Switzerland, Belgium, Spain, Portugal, Italy